June 30 (Reuters) - AbbVie (ABBV.N), opens new tab said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product ...

I fell in love with cable driven mechanisms a few years ago and put together some of my first mechanical tentacles to celebrate. But only after playing with them did I start to understand the ...

AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1bn, adding a “high-risk, high-reward” clinical-stage in vivo CAR-T candidate to its pipeline. Capstan is developing a new type of CAR-T ...

AbbVie is making a full strength play for the in vivo CAR-T market, snapping up Capstan Therapeutics for $2.1 billion to add an early-phase autoimmune drug candidate to its pipeline. Capstan is part ...

A University of Pennsylvania biotechnology company that aims to treat autoimmune diseases by reengineering cells within the body is being acquired by pharmaceutical giant AbbVie for $2.1 billion in ...

SAN DIEGO--(BUSINESS WIRE)--Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery utilizing targeted lipid ...

SAN DIEGO & PHILADELPHIA--(BUSINESS WIRE)--Capstan Therapeutics, Inc., a biotechnology company dedicated to developing and delivering precise in vivo cell engineering to patients, launched today with ...

AbbVie wasn’t part of the first wave of cell therapies developed for cancer, but it is positioning itself to contend in the next one, which is expanding to therapies made by engineering immune cells ...

AbbVie announced this morning it would buy clinical-stage biotech company Capstan Therapeutics for up to $2.1 billion in cash, picking up the company's in vivo CAR-T therapy candidate. San Diego-based ...

A startup that aims to integrate robotics with minimally invasive heart valve procedures has collected $31.4 million in venture capital funding. While robots have made inroads in many different types ...